Linked biaryl compounds
View Patent ↗Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.
1. A compound having the formula (Ia):
R 1 O 2 C—CR a R b —Y—Ar 1 —X—Ar 2 -Z 1 -Z 2 -Ar 3 Ia
or a pharmaceutically acceptable salt or prodrug thereof, wherein
X is selected from the group consisting of O, S(O) m , CR′R″ and SO 2 NR″;
Y is O or CR′R″;
Z 1 is O or CR′R″;
Z 2 is CR′R″C(O)NR′″;
Ar 1 and Ar 2 are independently phenyl;
Ar 3 is aryl;
R 1 is selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl and aryl(C 1 -C 4 )alkyl;
R a and R b are independently selected from the group consisting of hydrogen, (C 1 -C 4 )alkyl, aryl and aryl(C 1 -C 4 )alkyl;
each R′, R″ and R′″ is independently selected from the group consisting of hydrogen, (C 1 -C 4 )alkyl, aryl and aryl(C 1 -C 4 )alkyl; and
the subscript m is an integer from 0 to 2.
2. The compound of claim 1 , wherein Ar 3 is selected from the group consisting of phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzimidazolyl, indolyl, isoquinolyl and quinolyl.
3. The compound of claim 1 , having the formula (Ib):
wherein
R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )alkyl, (C 5 -C 6 )cycloalkyl, fluoro(C 1 -C 4 )alkyl, OR′, aryl, aryl(C 1 -C 4 )alkyl, NO 2 , NR′R″, C(O)R′, CO 2 R, C(O)NR′R″, N(R″)C(O)R′, N(R″)CO 2 R′, N(R″)C(O)NR′R″, S(O) m NR′R″, S(O) m R′, CN and N(R″)S(O) m R′;
optionally, when R′ and R″ are attached to the same nitrogen atom, R′ and R″ may be combined with the nitrogen atom to form a 5-, 6- or 7-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, O and S; and
optionally, any two adjacent R groups selected from the group consisting of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 may be combined with the carbon atoms to which they are attached to form a fused aromatic or cycloalkane ring.
4. The compound of claim 3 , wherein R a and R b are both hydrogen or methyl.
5. The compound of claim 3 , wherein Ar 3 is selected from the group consisting of substituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl, substituted or unsubstituted benzothiazolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted indolyl, substituted or unsubstituted isoquinolyl and substituted or unsubstituted quinolyl.
6. The compound of claim 3 , wherein Ar 3 is phenyl or pyridyl.
7. The compound of claim 3 , wherein Ar 3 is 2-pyridyl, 3-pyridyl or 4-pyridyl.
8. The compound of claim 7 , having the formula (IV):
wherein
R 2′ , R 3′ , R 4′ and R 5′ are independently selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )alkyl, fluoro(C 1 -C 4 )alkyl, OR′, aryl, aryl(C 1 -C 4 )alkyl, NO 2 , NR′R″, C(O)R′, CO 2 R, C(O)NR′R″, N(R″)C(O)R′, N(R″)CO 2 R′, N(R″)C(O)NR′R″, S(O) m NR′R″, S(O) m R′, CN and N(R″)S(O) m R′.
9. The compound of claim 3 , wherein X is selected from the group consisting of S(O) m , CH 2 , C(CH 3 ) 2 and SO 2 NR″.
10. The compound of claim 3 , wherein X is selected from the group consisting of S(O) m , CH 2 , C(CH 3 ) 2 and SO 2 NR″ and Y is O.
11. The compound of claim 3 , wherein X is S and Y is O.
12. The compound of claim 3 , wherein X is selected from the group consisting of S(O) m , CH 2 , C(CH 3 ) 2 and SO 2 NR″ and Z 1 is O.
13. The compound of claim 3 , wherein Ar 3 is phenyl or pyridyl and X is selected from the group consisting of S(O) m , CR′R″ and SO 2 NR″.
14. The compound of claim 3 , wherein Ar 3 is phenyl or pyridyl, X is selected from the group consisting of S(O) m , CH 2 , C(CH 3 ) 2 and SO 2 NR″ and Y is O.
15. The compound of claim 3 , wherein Ar 3 is phenyl or pyridyl, X is S and Y is O.
16. The compound of claim 3 , wherein Ar 3 is phenyl or pyridyl and Z 1 is O.
17. The compound of claim 3 , wherein Ar 3 is phenyl or pyridyl and X is selected from the group consisting of S(O) m , CH 2 , C(CH 3 ) 2 and SO 2 NR″.
18. The compound of claim 17 , wherein Z 1 is CH 2 .
19. The compound of claim 17 , wherein Z 1 is CR′R″.
20. The compound of claim 17 , wherein Z 1 is O.
21. The compound of claim 20 , or a pharmaceutically acceptable salt or prodrug thereof, wherein said compound is
22. The compound of claim 3 , wherein
X is selected from the group consisting of S(O) m , CH 2 , C(CH 3 ) 2 and SO 2 NR″;
Y is O;
Ar 3 is selected from the group consisting of phenyl, oxazolyl, thiazolyl, pyridyl, benzimidazolyl and quinolyl;
R 1 is selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl and aryl(C 1 -C 4 )alkyl;
R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen and (C 1 -C 4 )alkyl and (C 5 -C 6 )cycloalkyl;
optionally, any two adjacent R groups selected from the group consisting of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 may be combined with the carbon atoms to which they are attached to form a fused benzene or cyclohexane ring;
R a and R b are hydrogen;
each R′, R″ and R′″ is independently selected from the group consisting of hydrogen, (C 1 -C 4 )alkyl, aryl and aryl(C 1 -C 4 )alkyl;
optionally, when R′and R″are attached to the same nitrogen atom, R′ and R″ may be combined with the nitrogen atom to form a 5-, 6- or 7-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, O and S; and
the subscript m is an integer from 0 to 2.
23. The compound of claim 3 , wherein
X is selected from the group consisting of S, SO 2 and CH 2 ;
Y is O;
Ar 3 is selected from the group consisting of phenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-oxazolyl, 5-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-benzimidazolyl, 4-quinolyl, 5-quinolyl and 6-quinolyl;
R 1 is hydrogen;
R 2 , R 3 , R 4 , R 6 and R 7 are independently selected from the group consisting of hydrogen, chlorine, methyl, ethyl, n-propyl, isopropyl and cyclopentyl;
optionally, R 2 and R 3 are combined with the carbon atoms to which they are attached to form a fused benzene or cyclohexane ring;
optionally, R 6 and R 7 are combined with the carbon atoms to which they are attached to form a fused benzene ring;
R 5 , R 8 and R 9 are each hydrogen;
R a and R b are hydrogen;
each R′, R″ and R′″ is independently selected from the group consisting of hydrogen, (C 1 -C 4 )alkyl, aryl and aryl(C 1 -C 4 )alkyl;
optionally, when R′ and R″ are attached to the same nitrogen atom, R′ and R″ may be combined with the nitrogen atom to form a 5-, 6- or 7-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, O and S.
24. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and a compound according to claim 1 .